Table 2.
Study-level characteristicsa of included trials
| Study | Concealment of randomization | Blinding of assessor to outcome treatment group | Intention to treat strategy | A priori power estimation | Composite conditionsb | Dropouts during follow up |
|---|---|---|---|---|---|---|
| Staat et al5 | 0 | 1 | 0 | 0 | 0 | 0 |
| Laskey13 | 0 | 0 | 1 | 0 | 0 | 0 |
| Ma et al14 | 0 | 1 | 0 | 0 | 0 | 0 |
| Yang et al6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thibault et al7 | 1 | 1 | 1 | 1 | 1 | 0 |
| Laskey et al15 | 1 | 1 | 1 | 1 | 1 | 0 |
| Lønborg et al45 | 1 | 1 | 1 | 1 | 1 | 1 |
| Sörensson et al9 | 1 | 1 | 1 | 1 | 1 | 1 |
| Xue et al17 | 0 | 1 | 0 | 0 | 0 | 0 |
| Lin et al18 | 1 | 1 | 1 | 0 | 0 | 0 |
| Garcia et al19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liu et al20 | 1 | 0 | 1 | 0 | 0 | 0 |
| Freixa et al11 | 1 | 1 | 1 | 1 | 1 | 1 |
| Zhao et al21 | 0 | 1 | 1 | 0 | 0 | 0 |
| Tarantini et al10 | 1 | 1 | 1 | 1 | 1 | 1 |
| Thuny et al22 | 1 | 1 | 1 | 0 | 0 | 1 |
| Elżbieciak et al23 | 1 | 1 | 1 | 0 | 0 | 0 |
| Dwyer et al24 | 1 | 1 | 1 | 1 | 1 | 1 |
| Hahn et al25 | 1 | 1 | 1 | 1 | 1 | 1 |
| Dong et al26 | 1 | 1 | 1 | 0 | 0 | 1 |
| Limalanathan et al12 | 1 | 1 | 1 | 1 | 1 | 1 |
Notes:
a
1= presence of the condition, 0= absence of the condition or unclear;
b
composite variable that has the value of 1 when the following conditions are respected or present simultaneously: concealment of randomization, end point assessor blinded to treatment group, intention-to-treat strategy, and a priori power estimation (nonbiased and powered studies).